Background: Pentoxifylline (PTX) is a drug commonly used in the treatment of intermittent claudication. However, numerous research groups report that PTX also may potentially be used in the anticancer therapy following one of the main trends in the nowadays medicine - combined anticancer therapy.
Scope Of Review: The review concentrates on the reports revealing the potential use of PTX in cancer treatment. Major Conclusion: PTX is described to possess several properties which may be exploited in cancer treatment. The drug reportedly not only has anticancer activity itself, but also increases cancer cells susceptibility to radiation therapy and, additionally, reduces long-term side effects of this therapy. Furthermore, numerous research groups report that PTX may increase the anticancer potential of commonly used anticancer drugs such as cisplatin or doxorubicin as well as reduce side effects of these drugs.
Significance: PTX should be considered as a potential drug in the combined anticancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1389201019666180528084641 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical Alzheimer's prevention trials require a multi-year commitment from diverse, cognitively unimpaired individuals willing to receive biomarker results of confirmed Alzheimer's pathology and possible ApoE4 status. Participants learn new terms such as ARIA, edema and microhemorrhage and undergo numerous MRI scans for safety monitoring. They take quarterly composite Alzheimer's assessments that are anxiety-provoking and highlight weaknesses which may have been unrecognized in daily life.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Numerous drugs (including disease-modifying therapies, cognitive enhancers and neuropsychiatric treatments) are being developed for Alzheimer's and related dementias (ADRD). Emerging neuroimaging modalities, and genetic and other biomarkers potentially enhance diagnostic and prognostic accuracy. These advances need to be assessed in real-world studies (RWS).
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Indiana University School of Medicine, Department of Psychiatry, Indianapolis, IN, USA.
Background: Major contributors to AD pathogenesis include aggregates of amyloid-β (Aβ) peptides, hyperphosphorylated tau protein, and neuroinflammation. No currently approved treatment stops or significantly slows the progression of AD. Nevertheless, one class of agents that has shown promise is metal chelators.
View Article and Find Full Text PDFA Retrospective Comparison of Aeroallergen Sensitization Among Different Allergic Diseases in Guangzhou, China.
Mediators Inflamm
January 2025
Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
Numerous studies have reported on the types of aeroallergen sensitization in various pediatric allergic diseases, but limited data compared the types of aeroallergen sensitization across different pediatric allergic diseases. The aim of this study is to explore the nature and significance of aeroallergen sensitization in diverse pediatric allergic conditions. A comparative analysis was carried out on aeroallergen sensitization in children suffering from allergic diseases who visited the Otolaryngology, Respiratory, and Dermatology Departments between January 2019 and December 2023.
View Article and Find Full Text PDFThe Relationship Between ADAMTS-4 and ADAMTS-5 Enzyme Levels in Patients With Degenerative Disc Disease: A Prospective Biochemical Study.
JOR Spine
March 2025
Department of Neurosurgery Celal Bayar University, Faculty of Medicine Manisa Turkey.
Study Design: Prospective biochemical study of comparison of A Disintegrin and Metalloproteinase with Thrombospondin motifs-4 (ADAMTS-4) and A Disintegrin and Metalloproteinase with Thrombospondin motifs 5 (ADAMTS5) levels in preoperative and postoperative venous blood, as well as in disc tissue obtained during surgery, in patients undergoing surgery for intervertebral disc disease, with enzyme levels in venous blood from a control group.
Objective: To compare the levels of ADAMTS-4 and ADAMTS-5 between patients with degenerative intervertebral discs and a healthy control group, aiming to identify biomarkers associated with intervertebral disc degeneration.
Literature: Although numerous studies have investigated the relationship between ADAMTS-4 and ADAMTS-5 enzymes and degeneration in experimental rat models and human tissues, no study has correlated their serum levels with intervertebral disc degeneration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!